| US 7,563,442 B2 | ||
| Antibodies to CD40 and methods of treating cancer and enhancing immune responses | ||
| Vahe Bedian, East Lyme, Conn. (US); Ronald P Gladue, Stonington, Conn. (US); Jose Corvalan, Foster City, Calif. (US); Xiao-Chi Jia, San Mateo, Calif. (US); and Xiao Feng, Union City, Calif. (US) | ||
| Assigned to Abgenix, Inc., Fremont, Calif. (US); and Pfizer Inc., New York, N.Y. (US) | ||
| Filed on Aug. 26, 2005, as Appl. No. 11/213,575. | ||
| Application 11/213575 is a division of application No. 10/292088, filed on Nov. 08, 2002, granted, now 7,288,251, filed on Oct. 30, 2007. | ||
| Claims priority of provisional application 60/348980, filed on Nov. 09, 2001. | ||
| Prior Publication US 2007/0190051 A1, Aug. 16, 2007 | ||
| Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01) | ||
| U.S. Cl. 424—153.1 [424/130.1; 424/133.1; 424/141.1; 424/143.1; 424/144.1; 424/173.1; 530/387.1; 530/387.3; 530/388.2; 530/388.22; 530/388.7] | 133 Claims |
| 1. A monoclonal antibody or an antigen-binding portion thereof that specifically binds to and activates human CD40, wherein
said antibody comprises:
(a) a heavy chain CDR1 amino acid sequence, CDR2 amino acid sequence, and CDR3 amino acid sequence, respectively, of amino
acid residues 26-35, 50-66, and 99-115 of SEQ ID NO: 2; and a light chain CDR1 amino acid sequence, CDR2 amino acid sequence,
and CDR3 amino acid sequence, respectively, of amino acid residues 24-39, 55-61, and 94-102 of SEQ ID NO: 4;
(b) a heavy chain CDR1 amino acid sequence, CDR2 amino acid sequence, and CDR3 amino acid sequence, respectively, of amino
acid residues 26-35, 50-66, and 99-115 of SEQ ID NO: 90; and a light chain CDR1 amino acid sequence, CDR2 amino acid sequence,
and CDR3 amino acid sequence, respectively, of amino acid residues 24-39, 55-61, and 94-102 of SEQ ID NO: 4;
(c) a heavy chain CDR1 amino acid sequence, CDR2 amino acid sequence, and CDR3 amino acid sequence, respectively, of amino
acid residues 26-35, 50-66, and 99-115 of SEQ ID NO: 92; and a light chain CDR1 amino acid sequence, CDR2 amino acid sequence,
and CDR3 amino acid sequence, respectively, of amino acid residues 24-39, 55-61, and 94-102 of SEQ ID NO: 4;
(d) a heavy chain CDR1 amino acid sequence, CDR2 amino acid sequence, and CDR3 amino acid sequence, respectively, of amino
acid residues 26-35, 50-66, and 99-115 of SEQ ID NO: 2; and a light chain CDR1 amino acid sequence, CDR2 amino acid sequence,
and CDR3 amino acid sequence, respectively, of amino acid residues 24-39, 55-61, and 94-102 of SEQ ID NO: 94;
(e) a heavy chain CDR1 amino acid sequence, CDR2 amino acid sequence, and CDR3 amino acid sequence, respectively, of amino
acid residues 26-35, 50-66, and 99-115 of SEQ ID NO: 90; and a light chain CDR1 amino acid sequence, CDR2 amino acid sequence,
and CDR3 amino acid sequence, respectively, of amino acid residues 24-39, 55-61, and 94-102 of SEQ ID NO: 94; or
(f) a heavy chain CDR1 amino acid sequence, CDR2 amino acid sequence, and CDR3 amino acid sequence, respectively, of amino
acid residues 26-35, 50-66, and 99-115 of SEQ ID NO: 92; and a light chain CDR1 amino acid sequence, CDR2 amino acid sequence,
and CDR3 amino acid sequence, respectively, of amino acid residues 24-39, 55-61, and 94-102 of SEQ ID NO: 94.
|